<DrugInformationSummary id="CDR0000575327"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>This page contains brief information about nilotinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/nilotinib">Nilotinib</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000435988">nilotinib hydrochloride monohydrate</TerminologyLink><GlossaryLink ref="CDR0000575396">nilotinib</GlossaryLink><USBrandNames><USBrandName>Tasigna</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>ny-LOH-tih-nib</TermPronunciation><MediaLink ref="CDR0000721206" type="audio/mpeg" alt="" language="en" id="_5"/><MediaLink ref="CDR0000721205" type="audio/mpeg" alt="" language="es" id="_6"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Nilotinib</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Nilotinib is approved to treat:</Para><ItemizedList Style="bullet" id="_4"><ListItem><Strong><GlossaryTermRef href="CDR0000044901" dictionary="Cancer.gov" audience="Patient">Chronic myelogenous leukemia</GlossaryTermRef></Strong> (CML) that is <GlossaryTermRef href="CDR0000044179" dictionary="Cancer.gov" audience="Patient">Philadelphia chromosome</GlossaryTermRef> <GlossaryTermRef href="CDR0000044710" dictionary="Cancer.gov" audience="Patient">positive</GlossaryTermRef>. It is used:<ItemizedList Style="bullet" id="_5"><ListItem>In adults and children aged 1 year or older with newly <GlossaryTermRef href="CDR0000046450" dictionary="Cancer.gov" audience="Patient">diagnosed</GlossaryTermRef> <GlossaryTermRef href="CDR0000045160" dictionary="Cancer.gov" audience="Patient">chronic phase CML</GlossaryTermRef>.
</ListItem><ListItem>In adults with chronic phase or <GlossaryTermRef href="CDR0000046212" dictionary="Cancer.gov" audience="Patient">accelerated phase CML</GlossaryTermRef> that cannot be treated with or that did not <GlossaryTermRef href="CDR0000044085" dictionary="Cancer.gov" audience="Patient">respond</GlossaryTermRef> to treatment that included <GlossaryTermRef href="CDR0000044893" dictionary="Cancer.gov" audience="Patient">imatinib mesylate</GlossaryTermRef>.</ListItem><ListItem>In children aged 1 year or older with chronic phase CML that cannot be treated with or that did not respond to <GlossaryTermRef href="CDR0000044833" dictionary="Cancer.gov" audience="Patient">tyrosine kinase inhibitor</GlossaryTermRef> <GlossaryTermRef href="CDR0000044737" dictionary="Cancer.gov" audience="Patient">therapy</GlossaryTermRef>.</ListItem></ItemizedList></ListItem></ItemizedList><Para id="_3">Nilotinib is also being studied in the treatment of other  types of cancer.</Para></Section><Section id="_About"><Title>More About Nilotinib</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/435988">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para>

<Para id="_About_8.16">MedlinePlus Information on <ExternalRef xref="https://medlineplus.gov/druginfo/meds/a608002.html">Nilotinib</ExternalRef> - A lay language summary of important information about this drug that may include the following:</Para>
<ItemizedList Style="bullet" id="_About_9.17"><ListItem>warnings about this drug,</ListItem><ListItem>what this drug is used for and how it is used,</ListItem><ListItem>what you should tell your doctor before using this drug,</ListItem><ListItem>what you should know about this drug before using it, </ListItem><ListItem>other drugs that may interact with this drug, and</ListItem><ListItem>possible side effects.  </ListItem></ItemizedList><Para id="_About_10.18">Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for.  This patient information sheet applies only to approved uses of the drug.  However, much of the information may also apply to unapproved uses that are being studied.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C95229">Find Clinical Trials for Nilotinib Hydrochloride Monohydrate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2008-02-01</DateFirstPublished><DateLastModified>2023-12-01</DateLastModified></DrugInformationSummary>
